Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Can J Cardiol ; 24(7): 561-7, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18612498

RESUMO

BACKGROUND: High blood pressure (BP) is an established and modifiable cardiovascular risk factor; however, awareness and management of this primarily asymptomatic disease remains suboptimal. OBJECTIVES: The Airdrie Community Hypertension Awareness and Management Program (A-CHAMP) was a community-based BP program for seniors designed to improve public and health care provider awareness and management of hypertension. METHODS: Volunteer peer health educators (VPHEs) were recruited from the community and trained to manage BP screening sessions in local pharmacies. Airdrie (Alberta) residents 65 years of age and older were invited by their family physicians (FPs) to attend the A-CHAMP sessions. VPHEs identified participants' cardiovascular risk factors, assessed BP with a validated automated device and implemented a management algorithm. Participants with BP higher than 159/99 mmHg were directed to their pharmacists and FPs. All participants with elevated BP at the initial A-CHAMP session were invited to return to a follow-up session four to six months later. RESULTS: Thirty VPHEs were recruited and trained. All 15 FPs and all six pharmacies in Airdrie participated. VPHEs assessed 406 seniors (approximately 40% of Airdrie seniors) during the three-month program. One hundred forty-eight participants (36.5%) had elevated BP at their first session. Of these, 71% returned for the follow-up session four to six months later. The mean (+/- SD) systolic BP decreased by 16.9+/-17.2 mmHg (P<0.05, n=105) compared with their first visit, and 56% of participants (59 of 105) reached Canadian targets for BP. CONCLUSIONS: A-CHAMP raised awareness, and identified and managed seniors with hypertension. At follow-up, BP showed statistically and clinically significant and sustained improvement. Participating health care providers and VPHEs indicated that A-CHAMP was effective and feasible in improving awareness and control of hypertension.


Assuntos
Conscientização , Conhecimentos, Atitudes e Prática em Saúde , Pessoal de Saúde/normas , Hipertensão/terapia , Avaliação de Resultados em Cuidados de Saúde/métodos , Avaliação de Programas e Projetos de Saúde , Idoso , Alberta/epidemiologia , Pressão Sanguínea/fisiologia , Feminino , Seguimentos , Humanos , Hipertensão/epidemiologia , Masculino , Prevalência , Estudos Retrospectivos , População Rural , Índice de Gravidade de Doença
2.
Curr Drug Metab ; 8(1): 1-7, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17266519

RESUMO

Tert-butylhydroquinone (tBHQ) has been commonly used as a synthetic food antioxidant to prevent oils and fats from oxidative deterioration and rancidity due to its potent anti-lipid peroxidation activity. In North America, the maximum level of tBHQ allowed in fat products is 0.02% with an acceptable daily intake of 0-0.7 mg/kg body weight. Extensive studies have demonstrated that tBHQ exhibit anti-carcinogenic effect. The ability of tBHQ to induce phase II xenobiotic metabolizing enzymes through an Nrf2-dependent pathway is thought to be responsible for the observed protective effect of tBHQ. It has been proposed that tBHQ enhances Nrf2-mediated transcription by promoting reactive oxygen species-mediated dissociation of Nrf2-Keap1, Nrf2 stabilization, phosphatidylinositol 3-kinase (PI3K)/Akt activity, and MAPK pathway activation. In contrast to the beneficial effects of tBHQ, a number of studies have shown that chronic exposure to tBHQ may induce carcinogenicity. However, the precise mechanisms of tBHQ carcinogenicity are not well understood. The toxicity or carcinogenicity of tBHQ has been attributed to the formation of reactive GSH-conjugates, generation of reactive species, CYP1A1 induction, caspase activation and reduced GSH/ATP levels. This review provides an account of recent mechanisms proposed for both chemoprotective and carcinogenic effect of tBHQ.


Assuntos
Anticarcinógenos/farmacologia , Carcinógenos/farmacologia , Hidroquinonas/farmacologia , Animais , Anticarcinógenos/farmacocinética , Antioxidantes/farmacocinética , Antioxidantes/farmacologia , Carcinógenos/farmacocinética , Conservantes de Alimentos/farmacocinética , Conservantes de Alimentos/farmacologia , Humanos , Hidroquinonas/farmacocinética , Mutagênicos/farmacocinética , Mutagênicos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...